Search results
Added:
1 year ago
A single centre, prospective, non-randomised study from DrDaniela Trabattoni (Monzino Cardiology Centre,Milan, IT) following device implantation of the Occlutech PFO Closure device in 442 consecutive patients.The study is particularly interesting due to the scarcity of data available on the long term follow up (over 5 years after) of device implantation. Also, the results are focussed not only…
View more
Added:
4 weeks ago
HFSA 25 - CCM-D was associated with successful defibrillation and symptom improvement in patients with HFrEF at 6 months in the INTEGRA-D Trial.Dr Nir Uriel (NewYork-Presbyterian, Columbia University Irving Medical Center, US) joins us to discuss findings from the Integra-D trial, evaluating a novel implantable device that provides both cardiac contractility modulation and defibrillation…
View more
Added:
2 weeks ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device…
View more
Added:
2 weeks ago
Gain essential insights into the pivotal trials and procedural techniques shaping transcatheter mitral valve replacement with Dr Mayra GuerreroThis presentation, part of Women As One's comprehensive Structural Interventions track, provides timely analysis of the landmark SUMMIT and ENCIRCLE trials that are defining the future of dedicated mitral devices.Drawing from clinical trial data showing…
View more
Added:
2 weeks ago
Navigate the complexities of patient selection and device matching in TMVR with Dr Ignacio Inglessis-AzuajeThis presentation, part of Women As One's comprehensive Structural Interventions track, provides essential guidance for clinicians approaching this rapidly evolving field. The presentation systematically explores general eligibility requirements including symptomatic severity, surgical risk…
View more
Added:
2 years ago
In this video series, first presented at the ESC Congress 2023 held in Amsterdam, Prof Roxana Mehran, Dr Antoinette Neylon, Dr Martin Swaans, Prof Raphael Rosenhek and Prof Haim Danenberg discuss the Expand II TAVR pivotal trial design and the rational for investigating the treatment of moderate aortic stenosis patients with Evolut™ TAVI, provide practical Echo imaging recommendations to improve…
View more
ESC 25: SWEDEPAD 1 and 2
Added:
2 months ago
Video
Added:
1 year ago
TCT Conference 2024 - Routine use of orbital atherectomy system (OAS) did not improve minimal stent area (MSA) or target vessel failure (TVF) at one year compaared to conventional balloon angioplasty.Dr Ajay J Kirtane (Columbia University Medical Center and New York-Presbyterian Hospital, New York, US) joins us onsite at TCT Conference to discuss the findings from ECLIPSE (NCT03108456; Abbott…
View more
Added:
1 year ago
AHA 2023 - Investigator, Dr Mandeep Mehra (Brigham and Women's Hospital, US) is interviewed by Dr Christian Inchaustegui (Oregon Health & Science University, US), CardioNerds Ambassador, on the findings of the ARIES HM3 trial (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES…
View more
Added:
1 year ago
HFA 24 - Dr Finn Gustafsson (Rigshospitalet, DK) joined us onsite at the Heart Failure Association Congress to discuss the findings from a subanalysis of the ARIES HeartMate 3 study (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two…
View more